Immune-related adverse events after a single dose of pembrolizumab

Eur J Cancer. 2021 May:148:92-94. doi: 10.1016/j.ejca.2021.01.048. Epub 2021 Mar 16.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / pathology*
  • Female
  • Humans
  • Non-Randomized Controlled Trials as Topic
  • Prognosis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab